AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Celcuity Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Celcuity Inc. (CELC) filed an 8-K detailing several capital-raising and financing actions dated 28 Jul 2025.

Loan amendment: The company executed a Second Amendment to its Amended & Restated Loan and Security Agreement with Innovatus and Oxford Finance. Key changes: (i) allows issuance of $150 m aggregate principal Convertible Senior Notes due 2031 and related capped-call transactions; (ii) permits equity conversion of the notes solely into common shares (cash only for fractional shares); (iii) requires a one-time $25 k amendment fee paid to Oxford; and (iv) extends to 9 May 2026 Innovatus� option to convert up to 20 % of Term A principal into CELC stock at $10.00 per share.

Capital markets activity: Celcuity launched a concurrent offering for $150 m of the Notes plus $75 m of common stock. Proceeds would strengthen liquidity and fund operations.

Additional debt capacity: Management believes the Phase 3 VIKTORIA-1 data achieve the “Term D Milestone,� enabling a $30 m Term D Loan draw by 31 Aug 2025.

Preliminary cash position: Cash, equivalents and short-term investments are expected at ~<$168.4 m> on 30 Jun 2025 versus $283.1 m a year earlier (-41 %). Figures are unaudited and subject to change.

Forward-looking statements caution that the offerings may not close, the Term D draw might not occur, and final June-quarter financials could differ.

Celcuity Inc. (CELC) ha presentato un modulo 8-K che descrive diverse azioni di raccolta capitali e finanziamento datate 28 luglio 2025.

Modifica del prestito: La società ha stipulato una Seconda Modifica al suo Contratto di Prestito e Garanzia Modificato e Ristabilito con Innovatus e Oxford Finance. Le modifiche principali sono: (i) autorizza l’emissione di Note Convertibili Senior per un importo aggregato di 150 milioni di dollari con scadenza 2031 e operazioni correlate di capped-call; (ii) consente la conversione azionaria delle note esclusivamente in azioni ordinarie (pagamento in contanti solo per le frazioni di azioni); (iii) richiede una commissione di modifica una tantum di 25.000 dollari da pagare a Oxford; e (iv) estende fino al 9 maggio 2026 l’opzione di Innovatus di convertire fino al 20% del capitale Term A in azioni CELC a 10,00 dollari per azione.

Attività sui mercati dei capitali: Celcuity ha avviato un’offerta simultanea per 150 milioni di dollari in Note più 75 milioni di dollari in azioni ordinarie. I proventi rafforzerebbero la liquidità e finanzerebbero le operazioni.

Capacità di indebitamento aggiuntiva: La direzione ritiene che i dati della Fase 3 VIKTORIA-1 raggiungano il “Term D Milestone�, consentendo un prelievo di 30 milioni di dollari dal prestito Term D entro il 31 agosto 2025.

Posizione di cassa preliminare: Si prevede che alla data del 30 giugno 2025 la liquidità, equivalenti e investimenti a breve termine siano circa 168,4 milioni di dollari, rispetto a 283,1 milioni di un anno prima (-41%). I dati non sono stati ancora revisionati e possono variare.

Le dichiarazioni previsionali avvertono che le offerte potrebbero non concludersi, il prelievo Term D potrebbe non avvenire e i risultati finanziari finali del trimestre di giugno potrebbero differire.

Celcuity Inc. (CELC) presentó un formulario 8-K detallando varias acciones de recaudación de capital y financiamiento con fecha 28 de julio de 2025.

Modificación del préstamo: La compañía ejecutó una Segunda Enmienda a su Acuerdo de Préstamo y Garantía Modificado y Restablecido con Innovatus y Oxford Finance. Cambios clave: (i) permite la emisión de Notas Convertibles Senior por un principal agregado de 150 millones de dólares con vencimiento en 2031 y transacciones relacionadas de capped-call; (ii) permite la conversión de las notas exclusivamente en acciones comunes (pago en efectivo solo para fracciones de acciones); (iii) requiere una tarifa de enmienda única de 25,000 dólares pagada a Oxford; y (iv) extiende hasta el 9 de mayo de 2026 la opción de Innovatus para convertir hasta el 20% del principal del Term A en acciones CELC a 10.00 dólares por acción.

Actividad en mercados de capital: Celcuity lanzó una oferta concurrente por 150 millones de dólares en Notas más 75 millones en acciones comunes. Los ingresos fortalecerían la liquidez y financiarían las operaciones.

Capacidad adicional de deuda: La gerencia cree que los datos de la Fase 3 VIKTORIA-1 alcanzan el “Term D Milestone�, habilitando un préstamo Term D de 30 millones de dólares para el 31 de agosto de 2025.

Posición preliminar de efectivo: Se espera que el efectivo, equivalentes e inversiones a corto plazo sean aproximadamente 168.4 millones de dólares al 30 de junio de 2025, frente a 283.1 millones un año antes (-41%). Las cifras no están auditadas y pueden cambiar.

Las declaraciones prospectivas advierten que las ofertas podrían no cerrarse, el préstamo Term D podría no realizarse y los resultados financieros finales del trimestre de junio podrían variar.

Celcuity Inc. (CELC)ëŠ� 2025ë…� 7ì›� 28ì¼ìž ìžë³¸ 조달 ë°� 금융 활ë™ì� ìƒì„¸íž� 설명í•� 8-K 보고서를 제출했습니다.

대ì¶� 수정: 회사ëŠ� Innovatus ë°� Oxford Finance와ì� 수정 ë°� ìž¬ìž‘ì„±ëœ ëŒ€ì¶� ë°� ë‹´ë³´ 계약ì—� 대í•� ë‘� 번째 ìˆ˜ì •ì•ˆì„ ì²´ê²°í–ˆìŠµë‹ˆë‹¤. 주요 ë³€ê²� ì‚¬í•­ì€ ë‹¤ìŒê³� 같습니다: (i) 2031ë…� 만기 ì´� 1ì–� 5천만 달러 규모ì� 전환사채 발행 ë°� ê´€ë � 캡드ì½� 거래 허용; (ii) 전환사채ë¥� 보통주로ë§� 전환 ê°€ëŠ�(소수 주ì‹ì—� 대해서ëŠ� 현금 지급만 허용); (iii) Oxfordì—� ì¼íšŒì„� 2ë§� 5ì²� 달러ì� 수정 수수ë£� ì§€ê¸� 요구; (iv) Innovatusê°€ 2026ë…� 5ì›� 9ì¼ê¹Œì§€ Term A ì›ê¸ˆì� 최대 20%ë¥� 주당 10달러ì—� CELC 주ì‹ìœ¼ë¡œ 전환í•� ìˆ� 있는 옵션 연장.

ìžë³¸ 시장 활ë™: CelcuityëŠ� 1ì–� 5천만 달러 규모ì� 전환사채와 7ì²� 5백만 달러 규모ì� 보통ì£� ë™ì‹œ 공모ë¥� 시작했습니다. 수ìµê¸ˆì€ 유ë™ì„� ê°•í™” ë°� ìš´ì˜ ìžê¸ˆìœ¼ë¡œ 사용ë� 예정입니ë‹�.

추가 ë¶€ì±� 한ë„: ê²½ì˜ì§„ì€ 3ìƒ� VIKTORIA-1 ë°ì´í„°ê°€ “Term D 마ì¼ìŠ¤í†¤â€ì„ 달성하여 2025ë…� 8ì›� 31ì¼ê¹Œì§€ 3천만 달러 규모ì� Term D 대ì¶� ì¸ì¶œì� 가능할 것으ë¡� ë³´ê³  있습니다.

예비 현금 위치: 2025ë…� 6ì›� 30ì� 기준 현금, 현금ì„� ìžì‚° ë°� 단기 투ìžê¸ˆì€ ì•� 1ì–� 6,840ë§� 달러ë¡�, ì „ë…„ ë™ê¸° 2ì–� 8,310ë§� 달러 대ë¹� 41% ê°ì†Œí•� 것으ë¡� 예ìƒë©ë‹ˆë‹�. 수치ëŠ� ê°ì‚¬ë˜ì§€ 않았으며 ë³€ë™ë  ìˆ� 있습니다.

미래 예측 진술ì—서ëŠ� 공모가 성사ë˜ì§€ ì•Šì„ ìˆ� 있으ë©�, Term D 대ì¶� ì¸ì¶œì� ì´ë£¨ì–´ì§€ì§€ ì•Šì„ ìˆ� 있고, 6ì›� 분기 최종 재무 결과가 달ë¼ì§� ìˆ� 있ìŒì� 경고하고 있습니다.

Celcuity Inc. (CELC) a déposé un formulaire 8-K détaillant plusieurs actions de levée de capitaux et de financement datées du 28 juillet 2025.

Modification du prêt : La société a exécuté un deuxième amendement à son contrat de prêt et de garantie modifié et restitué avec Innovatus et Oxford Finance. Principaux changements : (i) autorisation d’émettre des billets convertibles senior d’un montant principal global de 150 millions de dollars échéant en 2031 et opérations capped-call associées ; (ii) conversion des billets uniquement en actions ordinaires (paiement en espèces uniquement pour les fractions d’actions) ; (iii) exigence d’un frais d’amendement unique de 25 000 dollars payable à Oxford ; et (iv) prolongation jusqu’au 9 mai 2026 de l’option d’Innovatus de convertir jusqu’� 20 % du principal Term A en actions CELC au prix de 10,00 dollars par action.

Activité sur les marchés des capitaux : Celcuity a lancé une offre simultanée pour 150 millions de dollars de billets plus 75 millions de dollars d’actions ordinaires. Les produits renforceraient la liquidité et financeraient les opérations.

Capacité d’endettement supplémentaire : La direction estime que les données de la Phase 3 VIKTORIA-1 atteignent le « Term D Milestone », permettant un tirage de 30 millions de dollars sur le prêt Term D d’ici le 31 août 2025.

Position de trésorerie préliminaire : La trésorerie, les équivalents et les placements à court terme devraient s’établir à environ 168,4 millions de dollars au 30 juin 2025, contre 283,1 millions un an plus tôt (-41 %). Les chiffres ne sont pas audités et peuvent évoluer.

Les déclarations prospectives avertissent que les offres pourraient ne pas aboutir, que le tirage Term D pourrait ne pas se réaliser et que les résultats financiers définitifs du trimestre de juin pourraient différer.

Celcuity Inc. (CELC) reichte am 28. Juli 2025 ein 8-K ein, das mehrere Kapitalbeschaffungs- und Finanzierungsmaßnahmen detailliert beschreibt.

°­°ù±ð»å¾±³Ùä²Ô»å±ð°ù³Ü²Ô²µ: Das Unternehmen führte eine zweite Änderung seines geänderten und neu gefassten Darlehens- und Sicherungsabkommens mit Innovatus und Oxford Finance durch. Wichtige Änderungen: (i) erlaubt die Ausgabe von insgesamt 150 Mio. USD an wandelbaren Senior Notes mit Fälligkeit 2031 und damit verbundenen capped-call Transaktionen; (ii) erlaubt die Umwandlung der Notes ausschließlich in Stammaktien (Barausgleich nur für Bruchteile von Aktien); (iii) verlangt eine einmalige Änderungsgebühr von 25.000 USD an Oxford; und (iv) verlängert bis zum 9. Mai 2026 Innovatusâ€� Option, bis zu 20 % des Term A Kapitalbetrags in CELC-Aktien zu 10,00 USD pro Aktie umzuwandeln.

°­²¹±è¾±³Ù²¹±ô³¾²¹°ù°ì³Ù²¹°ì³Ù¾±±¹¾±³Ùä³Ù±ð²Ô: Celcuity startete ein gleichzeitiges Angebot über 150 Mio. USD der Notes plus 75 Mio. USD Stammaktien. Die Erlöse sollen die Liquidität stärken und den Geschäftsbetrieb finanzieren.

Zusätzliche Verschuldungskapazität: Das Management ist der Ansicht, dass die Phase-3-Daten von VIKTORIA-1 den „Term D Meilenstein� erreichen, was eine Abhebung eines Term D Darlehens in Höhe von 30 Mio. USD bis zum 31. August 2025 ermöglicht.

Vorläufige Liquiditätslage: Es wird erwartet, dass sich die liquiden Mittel, Äquivalente und kurzfristigen Anlagen zum 30. Juni 2025 auf etwa 168,4 Mio. USD belaufen, gegenüber 283,1 Mio. USD im Vorjahr (-41 %). Die Zahlen sind ungeprüft und können sich ändern.

Prognosehinweise warnen, dass die Angebote nicht abgeschlossen werden könnten, die Term D Abhebung möglicherweise nicht erfolgt und die endgültigen Finanzergebnisse für das Juni-Quartal abweichen können.

Positive
  • Access to >$255 m of fresh capital through notes, equity, and Term D Loan enhances liquidity runway.
  • Loan amendment extends Innovatus conversion window, reducing near-term refinancing pressure.
  • Achievement of Term D Milestone indicates progress in Phase 3 VIKTORIA-1 trial, potentially derisking the development program.
Negative
  • Cash balance fell 41 % YoY to $168.4 m, highlighting high burn rate.
  • Equity and convertible offerings introduce dilution risk for existing shareholders.
  • Additional $180 m of debt (notes + Term D) increases leverage and future interest obligations.

Insights

TL;DR: Amendment & capital raise boost liquidity but add dilution and leverage; net impact neutral.

The Second Amendment clears structural hurdles so Celcuity can layer in $150 m convertible notes, $75 m equity, and a $30 m Term D draw. Combined, potential gross proceeds exceed $255 m, significantly replenishing the cash balance that fell to $168 m. The capped call should limit conversion dilution near-term, yet eventual share issuance (notes at investor-set strike and lender conversion at $10) increases equity overhang. The incremental debt (Term D + notes) raises leverage, but the company gains flexibility ahead of pivotal clinical readouts. Absent revenue, liquidity runway is extended; however, investors must weigh dilution versus runway.

TL;DR: Financing signals confidence after VIKTORIA-1 data, but high cash burn persists.

Management’s belief it hit the Term D Milestone implies positive interpretation of PIK3CA WT cohort results, unlocking $30 m at favorable terms. The substantial twin offering suggests appetite from capital markets, reflecting trust in the HER2-altered breast-cancer program. Yet the 41 % YoY cash decline underscores intense trial spending. Investors should monitor dilution, milestone-based debt covenants, and upcoming topline updates that will ultimately determine the conversion economics and share performance.

Celcuity Inc. (CELC) ha presentato un modulo 8-K che descrive diverse azioni di raccolta capitali e finanziamento datate 28 luglio 2025.

Modifica del prestito: La società ha stipulato una Seconda Modifica al suo Contratto di Prestito e Garanzia Modificato e Ristabilito con Innovatus e Oxford Finance. Le modifiche principali sono: (i) autorizza l’emissione di Note Convertibili Senior per un importo aggregato di 150 milioni di dollari con scadenza 2031 e operazioni correlate di capped-call; (ii) consente la conversione azionaria delle note esclusivamente in azioni ordinarie (pagamento in contanti solo per le frazioni di azioni); (iii) richiede una commissione di modifica una tantum di 25.000 dollari da pagare a Oxford; e (iv) estende fino al 9 maggio 2026 l’opzione di Innovatus di convertire fino al 20% del capitale Term A in azioni CELC a 10,00 dollari per azione.

Attività sui mercati dei capitali: Celcuity ha avviato un’offerta simultanea per 150 milioni di dollari in Note più 75 milioni di dollari in azioni ordinarie. I proventi rafforzerebbero la liquidità e finanzerebbero le operazioni.

Capacità di indebitamento aggiuntiva: La direzione ritiene che i dati della Fase 3 VIKTORIA-1 raggiungano il “Term D Milestone�, consentendo un prelievo di 30 milioni di dollari dal prestito Term D entro il 31 agosto 2025.

Posizione di cassa preliminare: Si prevede che alla data del 30 giugno 2025 la liquidità, equivalenti e investimenti a breve termine siano circa 168,4 milioni di dollari, rispetto a 283,1 milioni di un anno prima (-41%). I dati non sono stati ancora revisionati e possono variare.

Le dichiarazioni previsionali avvertono che le offerte potrebbero non concludersi, il prelievo Term D potrebbe non avvenire e i risultati finanziari finali del trimestre di giugno potrebbero differire.

Celcuity Inc. (CELC) presentó un formulario 8-K detallando varias acciones de recaudación de capital y financiamiento con fecha 28 de julio de 2025.

Modificación del préstamo: La compañía ejecutó una Segunda Enmienda a su Acuerdo de Préstamo y Garantía Modificado y Restablecido con Innovatus y Oxford Finance. Cambios clave: (i) permite la emisión de Notas Convertibles Senior por un principal agregado de 150 millones de dólares con vencimiento en 2031 y transacciones relacionadas de capped-call; (ii) permite la conversión de las notas exclusivamente en acciones comunes (pago en efectivo solo para fracciones de acciones); (iii) requiere una tarifa de enmienda única de 25,000 dólares pagada a Oxford; y (iv) extiende hasta el 9 de mayo de 2026 la opción de Innovatus para convertir hasta el 20% del principal del Term A en acciones CELC a 10.00 dólares por acción.

Actividad en mercados de capital: Celcuity lanzó una oferta concurrente por 150 millones de dólares en Notas más 75 millones en acciones comunes. Los ingresos fortalecerían la liquidez y financiarían las operaciones.

Capacidad adicional de deuda: La gerencia cree que los datos de la Fase 3 VIKTORIA-1 alcanzan el “Term D Milestone�, habilitando un préstamo Term D de 30 millones de dólares para el 31 de agosto de 2025.

Posición preliminar de efectivo: Se espera que el efectivo, equivalentes e inversiones a corto plazo sean aproximadamente 168.4 millones de dólares al 30 de junio de 2025, frente a 283.1 millones un año antes (-41%). Las cifras no están auditadas y pueden cambiar.

Las declaraciones prospectivas advierten que las ofertas podrían no cerrarse, el préstamo Term D podría no realizarse y los resultados financieros finales del trimestre de junio podrían variar.

Celcuity Inc. (CELC)ëŠ� 2025ë…� 7ì›� 28ì¼ìž ìžë³¸ 조달 ë°� 금융 활ë™ì� ìƒì„¸íž� 설명í•� 8-K 보고서를 제출했습니다.

대ì¶� 수정: 회사ëŠ� Innovatus ë°� Oxford Finance와ì� 수정 ë°� ìž¬ìž‘ì„±ëœ ëŒ€ì¶� ë°� ë‹´ë³´ 계약ì—� 대í•� ë‘� 번째 ìˆ˜ì •ì•ˆì„ ì²´ê²°í–ˆìŠµë‹ˆë‹¤. 주요 ë³€ê²� ì‚¬í•­ì€ ë‹¤ìŒê³� 같습니다: (i) 2031ë…� 만기 ì´� 1ì–� 5천만 달러 규모ì� 전환사채 발행 ë°� ê´€ë � 캡드ì½� 거래 허용; (ii) 전환사채ë¥� 보통주로ë§� 전환 ê°€ëŠ�(소수 주ì‹ì—� 대해서ëŠ� 현금 지급만 허용); (iii) Oxfordì—� ì¼íšŒì„� 2ë§� 5ì²� 달러ì� 수정 수수ë£� ì§€ê¸� 요구; (iv) Innovatusê°€ 2026ë…� 5ì›� 9ì¼ê¹Œì§€ Term A ì›ê¸ˆì� 최대 20%ë¥� 주당 10달러ì—� CELC 주ì‹ìœ¼ë¡œ 전환í•� ìˆ� 있는 옵션 연장.

ìžë³¸ 시장 활ë™: CelcuityëŠ� 1ì–� 5천만 달러 규모ì� 전환사채와 7ì²� 5백만 달러 규모ì� 보통ì£� ë™ì‹œ 공모ë¥� 시작했습니다. 수ìµê¸ˆì€ 유ë™ì„� ê°•í™” ë°� ìš´ì˜ ìžê¸ˆìœ¼ë¡œ 사용ë� 예정입니ë‹�.

추가 ë¶€ì±� 한ë„: ê²½ì˜ì§„ì€ 3ìƒ� VIKTORIA-1 ë°ì´í„°ê°€ “Term D 마ì¼ìŠ¤í†¤â€ì„ 달성하여 2025ë…� 8ì›� 31ì¼ê¹Œì§€ 3천만 달러 규모ì� Term D 대ì¶� ì¸ì¶œì� 가능할 것으ë¡� ë³´ê³  있습니다.

예비 현금 위치: 2025ë…� 6ì›� 30ì� 기준 현금, 현금ì„� ìžì‚° ë°� 단기 투ìžê¸ˆì€ ì•� 1ì–� 6,840ë§� 달러ë¡�, ì „ë…„ ë™ê¸° 2ì–� 8,310ë§� 달러 대ë¹� 41% ê°ì†Œí•� 것으ë¡� 예ìƒë©ë‹ˆë‹�. 수치ëŠ� ê°ì‚¬ë˜ì§€ 않았으며 ë³€ë™ë  ìˆ� 있습니다.

미래 예측 진술ì—서ëŠ� 공모가 성사ë˜ì§€ ì•Šì„ ìˆ� 있으ë©�, Term D 대ì¶� ì¸ì¶œì� ì´ë£¨ì–´ì§€ì§€ ì•Šì„ ìˆ� 있고, 6ì›� 분기 최종 재무 결과가 달ë¼ì§� ìˆ� 있ìŒì� 경고하고 있습니다.

Celcuity Inc. (CELC) a déposé un formulaire 8-K détaillant plusieurs actions de levée de capitaux et de financement datées du 28 juillet 2025.

Modification du prêt : La société a exécuté un deuxième amendement à son contrat de prêt et de garantie modifié et restitué avec Innovatus et Oxford Finance. Principaux changements : (i) autorisation d’émettre des billets convertibles senior d’un montant principal global de 150 millions de dollars échéant en 2031 et opérations capped-call associées ; (ii) conversion des billets uniquement en actions ordinaires (paiement en espèces uniquement pour les fractions d’actions) ; (iii) exigence d’un frais d’amendement unique de 25 000 dollars payable à Oxford ; et (iv) prolongation jusqu’au 9 mai 2026 de l’option d’Innovatus de convertir jusqu’� 20 % du principal Term A en actions CELC au prix de 10,00 dollars par action.

Activité sur les marchés des capitaux : Celcuity a lancé une offre simultanée pour 150 millions de dollars de billets plus 75 millions de dollars d’actions ordinaires. Les produits renforceraient la liquidité et financeraient les opérations.

Capacité d’endettement supplémentaire : La direction estime que les données de la Phase 3 VIKTORIA-1 atteignent le « Term D Milestone », permettant un tirage de 30 millions de dollars sur le prêt Term D d’ici le 31 août 2025.

Position de trésorerie préliminaire : La trésorerie, les équivalents et les placements à court terme devraient s’établir à environ 168,4 millions de dollars au 30 juin 2025, contre 283,1 millions un an plus tôt (-41 %). Les chiffres ne sont pas audités et peuvent évoluer.

Les déclarations prospectives avertissent que les offres pourraient ne pas aboutir, que le tirage Term D pourrait ne pas se réaliser et que les résultats financiers définitifs du trimestre de juin pourraient différer.

Celcuity Inc. (CELC) reichte am 28. Juli 2025 ein 8-K ein, das mehrere Kapitalbeschaffungs- und Finanzierungsmaßnahmen detailliert beschreibt.

°­°ù±ð»å¾±³Ùä²Ô»å±ð°ù³Ü²Ô²µ: Das Unternehmen führte eine zweite Änderung seines geänderten und neu gefassten Darlehens- und Sicherungsabkommens mit Innovatus und Oxford Finance durch. Wichtige Änderungen: (i) erlaubt die Ausgabe von insgesamt 150 Mio. USD an wandelbaren Senior Notes mit Fälligkeit 2031 und damit verbundenen capped-call Transaktionen; (ii) erlaubt die Umwandlung der Notes ausschließlich in Stammaktien (Barausgleich nur für Bruchteile von Aktien); (iii) verlangt eine einmalige Änderungsgebühr von 25.000 USD an Oxford; und (iv) verlängert bis zum 9. Mai 2026 Innovatusâ€� Option, bis zu 20 % des Term A Kapitalbetrags in CELC-Aktien zu 10,00 USD pro Aktie umzuwandeln.

°­²¹±è¾±³Ù²¹±ô³¾²¹°ù°ì³Ù²¹°ì³Ù¾±±¹¾±³Ùä³Ù±ð²Ô: Celcuity startete ein gleichzeitiges Angebot über 150 Mio. USD der Notes plus 75 Mio. USD Stammaktien. Die Erlöse sollen die Liquidität stärken und den Geschäftsbetrieb finanzieren.

Zusätzliche Verschuldungskapazität: Das Management ist der Ansicht, dass die Phase-3-Daten von VIKTORIA-1 den „Term D Meilenstein� erreichen, was eine Abhebung eines Term D Darlehens in Höhe von 30 Mio. USD bis zum 31. August 2025 ermöglicht.

Vorläufige Liquiditätslage: Es wird erwartet, dass sich die liquiden Mittel, Äquivalente und kurzfristigen Anlagen zum 30. Juni 2025 auf etwa 168,4 Mio. USD belaufen, gegenüber 283,1 Mio. USD im Vorjahr (-41 %). Die Zahlen sind ungeprüft und können sich ändern.

Prognosehinweise warnen, dass die Angebote nicht abgeschlossen werden könnten, die Term D Abhebung möglicherweise nicht erfolgt und die endgültigen Finanzergebnisse für das Juni-Quartal abweichen können.

false 0001603454 0001603454 2025-07-28 2025-07-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 28, 2025

 

Celcuity Inc.

(Exact name of Registrant as Specified in its Charter)

 

Delaware   001-38207   82-2863566

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

16305 36th Avenue North, Suite 100
Minneapolis, Minnesota 55446

(Address of Principal Executive Offices and Zip Code)

 

(763) 392-0767

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value per share   CELC   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On July 28, 2025, Celcuity Inc. (the “Company”) entered into the Second Amendment to Amended and Restated Loan and Security Agreement (the “Second Amendment” and the existing Amended and Restated Loan Agreement, the “A&R Loan Agreement”) with Innovatus Life Sciences Lending Fund I, LP, a Delaware limited partnership (“Innovatus”), as collateral agent and a lender, Oxford Finance LLC, a Delaware limited liability company (“Oxford”), as a lender, and the other lenders party thereto, pursuant to which the A&R Loan Agreement was amended to (i) subject to certain terms and conditions, permit the issuance of the Notes (as defined below) and certain transactions in connection therewith, including the conversion thereof settled solely in common stock (together with cash in lieu of the issuance of any fractional share of common stock), (ii) permit the capped call transactions the Company expects to enter in connection with the pricing of the Notes, (iii) require an amendment fee payable by the Company to Oxford in the amount of $25,000, which was paid at the closing of the Second Amendment, and (iv) extend to May 9, 2026 the expiration date of Innovatus’ right to convert up to 20% of the outstanding principal of the Term A Loan (as defined in the A&R Loan Agreement) into shares of the Company’s common stock at a price per share of $10.00.

 

The foregoing description of the Second Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Second Amendment, which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

 

Item 8.01 Other Events.

 

Press Release

 

On July 28, 2025, the Company issued a press release announcing that it had launched a proposed concurrent offering (the “Offering”) to issue and sell (i) $150.0 million aggregate principal amount of Convertible Senior Notes due 2031 (the “Notes”) and (ii) $75.0 million of shares of the Company’s common stock. A copy of this press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

 

Term D Loan

 

Following the Company’s prior announcement of topline results from its PIK3CA wild-type cohort of Phase 3 VIKTORIA-1 clinical trial, the Company believes that it has achieved the Term D Milestone (as defined in the A&R Loan Agreement) and therefore is eligible to incur an additional $30.0 million of indebtedness under the Term D Loan (as defined in the A&R Loan Agreement). The Company intends to draw down such $30.0 million in late August 2025 prior to the expiration of the Term D Draw Period (as defined in the A&R Loan Agreement) on August 31, 2025.

 

Preliminary Financial Results as of June 30, 2025

 

The Company’s cash, cash equivalents and short-term investments are expected to be approximately $168.4 million as of June 30, 2025, as compared to $283.1 million as of June 30, 2024. The preceding preliminary financial information has been prepared by the Company’s management and should not be viewed as a substitute for full financial statements prepared in accordance with GAAP. The Company’s independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to this preliminary financial data or the accounting treatment thereof and does not express an opinion or any other form of assurance with respect thereto. The Company expects to complete its interim financial statements as of and for the three months and six months ended June 30, 2025 subsequent to the completion of the Offering. While the Company is currently unaware of any items that would require it to make adjustments to the preceding financial information, it is possible that the Company or its independent registered public accounting firm may identify such items in the process of completing the Company’s interim financial statements. Accordingly, undue reliance should not be placed on this preliminary financial information. This preliminary financial information is not necessarily indicative of any future period.

 

 
 

 

Forward-Looking Statements

 

This report contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 including statements relating to the proposed Offering, achievement of the Term D Milestone, our intent to incur an additional $30.0 million of indebtedness under the Term D Loan prior to the expiration of the Term D Draw Period, and our expectations regarding the completion of our financial statements as of and for the three months and six months ended June 30, 2025. Words such as, but not limited to, “look forward to,” “believe,” “expect,” “anticipate,” “estimate,” “intend,” “confidence,” “encouraged,” “potential,” “plan,” “targets,” “likely,” “may,” “will,” “would,” “should” and “could,” and similar expressions or words identify forward-looking statements. The forward-looking statements included in this report are based on management’s current expectations and beliefs which are subject to a number of risks, uncertainties and factors, including that our Offering may be delayed or terminated prior to completion, we may fail to draw the Term D Loan on or before the expiration of the Term D Draw Period, and we or our independent registered public accounting firm may identify unexpected adjustments that would change the preliminary financial information disclosure herein. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2024, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as such risks may be updated in our subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by these cautionary statements, and we undertake no obligation to revise or update this report to reflect events or circumstances after the date hereof.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

10.1   Second Amendment to Amended and Restated Loan and Security Agreement, dated May 13, 2025, by and among the Company, Innovatus Life Sciences Lending Fund I, LP, as collateral agent, the Lenders named therein and Oxford Finance LLC
99.1   Press release dated July 28, 2025
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 29, 2025

 

  CELCUITY INC.
   
  By: /s/ Brian F. Sullivan
    Brian F. Sullivan
    Chief Executive Officer

 

 

FAQ

What did Celcuity (CELC) amend in its loan agreement on July 28, 2025?

The Second Amendment permits issuance of $150 m convertible notes, allows capped calls, imposes a $25 k fee, and extends Innovatus� $10 conversion right to 9 May 2026.

How much capital is Celcuity aiming to raise in the new offerings?

The company launched a concurrent public offering of $150 m Convertible Senior Notes due 2031 and $75 m of common stock.

What is Celcuity’s preliminary cash balance as of June 30, 2025?

Management estimates cash, cash equivalents and short-term investments at approximately $168.4 million.

Has Celcuity met the Term D Milestone under its loan facility?

Celcuity believes the Phase 3 VIKTORIA-1 results satisfy the milestone, making it eligible to draw an additional $30 m before 31 Aug 2025.

Will the financial figures in the 8-K be audited?

No. The June 30, 2025 cash figure is preliminary and unaudited; final numbers will appear in upcoming interim financial statements.
Celcuity Inc

NASDAQ:CELC

CELC Rankings

CELC Latest News

CELC Latest SEC Filings

CELC Stock Data

521.42M
30.48M
13.73%
82.19%
7.98%
Biotechnology
Services-medical Laboratories
United States
MINNEAPOLIS